Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia | Blood Advances | American Society of Hematology
Key Points. Multiple- and single-dose subcutaneous rozanolixizumab infusions were effective and well tolerated in patients with primary ITP.Single rozanolixizu
Mahmoud Aljurf
126d ago
Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia. Single rozanolixizumab infusion increased platelet count and decreased IgG in patients with primary ITP by day 8 without serious infection
0